CLINICAL_TRIALS
trial_result
· 2019-02-25
Clinical Trial Update: Randomized Sitagliptin Withdrawal Study (MK-0431-845) [Phase 3]
Summary
A Phase 3 randomized withdrawal study of sitagliptin (MK-0431-845) in adults with type 2 diabetes mellitus has completed, with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-02-25